With regard to Health Canada’s (HC) authorization of the COVID-19 vaccines: did any of the manufacturers provide biodistribution studies to Canada’s regulatory agencies, departments, or other government entities, and, if so, (i) when were the studies provided, (ii) based on the biodistribution studies, where in the body was DNA or modified RNA, lipid nanoparticles and spike protein found, (iii) what percentage of the dose remained at the injection site at acute timepoints, (iv) for what period of time did this material remain in the organs or tissues of the body, including blood and bone marrow, (v) what was the period of time that biodistribution studies tracked this material in animal subjects, and was this time sufficient to confirm elimination of DNA, modified RNA, lipid nanoparticles and spike proteins, (vi) how many doses were evaluated in the biodistribution studies and did the researchers report any ill effects on the animals at any of the doses that were studied, (vii) were samples collected to evaluate the potential for shedding from the body, including in breast milk, (viii) if the answer to (vii) is affirmative, was shedding found in the breast milk, (ix) if the answer to (vii) is negative, why was it not required, (x) when did HC, the Public Health Agency of Canada, or the National Advisory Committee inform the Canadian public and the medical community where and for how long these products remain in the body?
In the House of Commons on January 29th, 2024. See this statement in context.